System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Xavier Durando is an expert in Oncology at Centre Jean Perrin (France). As of October 2026, ScienceLeadR ranks Xavier Durando in the top 1% of experts worldwide for Breast Diseases and Breast Neoplasms. Xavier Durando has authored 224 publications, the most recent in 2026, and is an investigator in 52 clinical trials, 17 of them ongoing. SLR score: 1,440 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Xavier Durando Centre Jean Perrin France
1 440 ScienceLeadR Reputation 1440

Unlock

Register Login
Network Map

Oncology

Subspecialties: Neurology - Public Health - Radiotherapy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Centre Jean Perrin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 224

Citations

Citations: 7 826 1st author: 11 Last author: 45 Unique author: 0

Main journals

J Clin Oncol 24
BMC Cancer 12
Cancer Res 12
Ann Oncol 9
Bull Cancer 8

Best Journals

J Clin Oncol 5
Lancet Oncol 5
Ann Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Impact of Implementing the Modified Assessment of the Difficulty of Intravenous Access Scale on First-Attempt Venous Access Success: Study Protocol for the Multicenter Prospective Before-and-After Controlled DIVAPERF Trial.
PMID 42857443 — nurses, therapeutics		Health Sci Rep20260
Study Protocol for Assessment of the Feasibility of an Intraoperative Localization Technique Using Augmented Reality in Breast-Conserving Surgery for Non-Palpable Cancer Lesions: A Feasibility Study.
PMID 42661930 — feasibility studies, breast neoplasms, augmented reality, neoplasms, breast, wounds and injuries		Health Sci Rep20260
Prospective multicentre study evaluating ctDNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: NeckTAR-IN protocol.
PMID 42567634 — radiotherapy, cells, blood, carcinoma, squamous cell, biomarkers, squamous cell carcinoma of head and neck, chemoradiotherapy, therapeutics		BMJ Open20260
Circulating proteins as biomarkers of response to cancer immunotherapy (Review).
PMID 42099246 — cells, lymphocytes, neoplasms, biomarkers, immunotherapy, therapeutics, t-lymphocytes, liquid biopsy		Int J Oncol20260
Patient-reported satisfaction with thermal water-based cosmetic products in breast cancer patients undergoing chemotherapy: a feasibility study.
PMID 41812302 — skin, feasibility studies, breast neoplasms, neoplasms, drug therapy, breast, therapeutics, chemotherapy		Cancer Treat Res Commun20260

Clinical Studies 52

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 11 Study Director: 1

By phase:

N/A 19
Phase 2 17
Phase 3 10
Phase 1/Phase 2 3
Early Phase 1 2
Phase 1 1

By status:

Completed 23
Recruiting 17
Active not recruiting 6
Terminated 4
Unknown 2

By type:

Interventional 45
Observational 7

By Monocentric/Multicentric:

monocentric 15
multicentric2to4 8
multicentric5to9 6
multicentricup10 23

Main Topics

Ongoing Clinical Trials

17 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer
2024-519655-28-00 — lymph nodes, breast neoplasms, neoplasms, multiple chronic conditions, neoplasm micrometastasis, lymph, breast, therapeutics, women		Phase 3Recruiting2026
Treatment for breast cancer patients with meninges invaded by tumor cells
2022-502351-60-00 — cells, breast neoplasms, neoplasms, neoplasm metastasis, breast, meninges, therapeutics, capecitabine, trastuzumab		Phase 2Recruiting2024
Clinical trial evaluating the activity of zanidatamab for the treatment of patients with solid tumors with an alteration of the HER2 gene
2025-522169-31-00 — cells, genes, lung, genes, erbb-2, neoplasms, carcinoma, non-small-cell lung, sarcoma, lung neoplasms, small cell lung carcinoma, therapeutics, endometrial neoplasms, head, neck		Phase 2Recruiting2025
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
NCT07178847 — cells, dna, complementary, blood, blood specimen collection, carcinoma, squamous cell, neoplasms, biomarkers, squamous cell carcinoma of head and neck, chemoradiotherapy, neoplasm, residual, carcinoma, head, neck		N/ARecruiting2025
Clinical trial evaluating the efficacy of pemigatinib for the treatment of patients with solid tumours with an alteration of the gene FGFR
2024-512729-10-00 — genes, neoplasms, therapeutics, mutation		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS